Carl Figdor, theme Cancer development and immune defense and Mihai Netea, theme Infectious diseases and global health, have each received an ERC Advanced Grant. The amount varies per grant, but is approximately 2.5 million euros. They can use this funding to continue their research for the next five years. In total, there are 21 ERC Advanced Grants granted to researchers of Dutch universities this year.Carl Figdor - A new approach to immunotherapy
In the ‘ARTimmune’ project, Carl Figdor focuses on the intriguing, novel idea of creating injectable synthetic lymph nodes to attack tumours more directly. His idea may have important implications for clinics. Currently, many cancer patients are failing to respond to immune therapy and new strategies are desperately needed. ARTimmune builds on the success and increasing popularity of immunotherapy in oncology, and seeks to overcome the key limitations of current treatments, such as serious side effects. Current treatments, such as CAR T-cell therapy and checkpoint inhibitors, can result in severe toxicity to normal tissues. Figdor wants to investigate a new approach in which the use of local immunotherapy reduces both toxicity and immune suppression by the tumour. ARTimmune is a direct result of the Institute of Chemical Immunology’s gravity programme, with Figdor being one of the initiators and in which chemists work closely together with immunologists.
Mihai Netea – improving vaccinations for the elderly
Mihai Netea seeks to understand how our body recognises all those pathogens and fights them effectively. Our immune system consists of an ‘innate’ and a ‘adaptive’ component. We receive this innate component at birth. The adaptive part can ‘learn’ from past infections and develops during our lifetime through direct contact with bacteria, fungi and viruses. The adaptive immune system component stores these contact situations in its immunological memory. Thanks to that memory, the immune system can strike quickly and effectively when a new infection of an already known pathogen is detected. It has long been thought that this memory is an exclusive feature of the learned defences. However, research by Mihai Netea and colleagues shows that this is not the case. The innate system also has a memory, albeit a non-specific one. Something they call ‘trained immunity’. They also discovered that the BCG vaccine against tuberculosis can stimulate the innate immune system’s memory. They demonstrated that the innate immune system responds better to all kinds of other infections after a BCG vaccination has been administered. Now Netea wants to investigate whether the vaccine can be used to boost the immune system of the elderly. Netea and his colleagues hope to clarify the role of different immune cells in trained immunity in order to ultimately determine whether the BCG vaccination can be useful for specific target groups with a weakened immune system.
More information about ERC Advanced grants at Radboud University you can find here.
Related news items
KWF Roadshow 11 November 201910 October 2019
In which way(s) can KWF provide optimal support to oncological research and care? How can we maximize impact on our investments? These questions are pivotal in Ambition 2030: the vision that KWF developed in close cooperation with stakeholders in the oncological field.read more
A personal touch of Frank Wagener10 October 2019
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Frank Wagener.read more
Dorine Swinkels collaborates with winners of the Nobel Prize in Physiology or Medicine9 October 2019
The Nobel Prize in Physiology or Medicine 2019 was awarded jointly to William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza for their discoveries of how cells sense and adapt to oxygen availability.read more
Scaling up nanotherapy7 October 2019
Scaling up and translating nanotherapy from pre-clinical work in small animal models to a clinical application is not trivial. Raphael Duivenvoorden, theme Renal disorders, and colleagues, published their results on translating a new nanoimmunotherapy in the journal Science Translational Medicine.read more